Breast cancer prevention: SERMs come of age

The Lancet

Volumn 381, Issue 9880, 2013, Pages 1795-1797

  Howell, Anthony ^a,c   Evans, D Gareth ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; ESTROGEN RECEPTOR; EXEMESTANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; ENDOMETRIUM; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HUMAN; MENARCHE; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SPINE FRACTURE;

EID: 84878115405     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60443-2     Document Type: Note

References (14)

1. Cuzick J, Sestak I, Bonanni B., et al, for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; published online April 30. http://dx.doi.org/10.1016/S0140- 6736(13)60140-3.
2. National Institute for Health and Clinical Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. October, 2006. http://www.nice.org.uk/ nicemedia/pdf/CG41NICEguidance.pdf (accessed March 14, 2013).
3. Freedm an A.N., Yu B, Gail M.H., et al Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011; 29: 2327-33.
4. Cuzick J, Forbes JF, Sestak I, et al; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
6. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
7. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-69.
8. Cuzick J, Warwick J, Pinney E., et al Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103: 744-52.
9. Cummings SR, Ensrud K, Delmas P.D., PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-96.
10. LaCroix AZ, Powles T, Osborne C.K., PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010; 102: 1706-15.
11. Goss PE, Ingle JN, Alés-Martínez JE, et al, NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-91.
12. Schmidt C. Third-generation SERMs may face uphill battle. J Natl Cancer Inst 2010; 102: 1690-92.
13. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976; 12: 419-24.
14. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2: 282.